Park Place Capital Corp Eye Point Pharmaceuticals, Inc. Transaction History
Park Place Capital Corp
- $291 Million
- Q2 2024
A detailed history of Park Place Capital Corp transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Park Place Capital Corp holds 23 shares of EYPT stock, worth $183. This represents 0.0% of its overall portfolio holdings.
Number of Shares
23
Previous 23
-0.0%
Holding current value
$183
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding EYPT
# of Institutions
163Shares Held
58.2MCall Options Held
224KPut Options Held
1.41M-
Cormorant Asset Management, LP Boston, MA8.33MShares$66.4 Million5.57% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.18MShares$41.3 Million1.88% of portfolio
-
Black Rock Inc. New York, NY3.76MShares$30 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.65MShares$29.1 Million0.01% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.59MShares$28.7 Million0.06% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $272M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...